Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

Arcus/Gilead Readout Expected Next

 
• By Andrew McConaghie
Roche_HQ
Roche has a lot riding on its SKYSCRAPER studies - and still hopes they will yield benefits for patients. • Source: Roche

More from Business

More from Scrip